APA (7th ed.) Citation

LR, M., M, A., TJ, A., GL, B., RJI, B., TE, B., . . . JB, T. (2026). Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): A multicentre, randomised, controlled, phase 3, non-inferiority trial. The lancet. Gastroenterology & hepatology, 11(7), 557. https://doi.org/10.1016/S2468-1253(26)00109-3

Chicago Style (17th ed.) Citation

LR, Moolenaar, et al. "Adjuvant Chemoradiotherapy Versus Completion Total Mesorectal Excision After Local Excision for Early Rectal Cancer (TESAR): A Multicentre, Randomised, Controlled, Phase 3, Non-inferiority Trial." The Lancet. Gastroenterology & Hepatology 11, no. 7 (2026): 557. https://doi.org/10.1016/S2468-1253(26)00109-3.

MLA (9th ed.) Citation

LR, Moolenaar, et al. "Adjuvant Chemoradiotherapy Versus Completion Total Mesorectal Excision After Local Excision for Early Rectal Cancer (TESAR): A Multicentre, Randomised, Controlled, Phase 3, Non-inferiority Trial." The Lancet. Gastroenterology & Hepatology, vol. 11, no. 7, 2026, p. 557, https://doi.org/10.1016/S2468-1253(26)00109-3.